Abstract 2310P
Background
The rapid proliferation of cancer cells leads to abnormal vascularization, creating a hypoxic tumor core in most advanced solid tumors. Recent studies have shown that hypoxia is associated with poor prognosis in cancer patients. Tumor aggressiveness is driven by hypoxia, which confers resistance to many conventional cancer therapies. In the present study, we propose that oxygen nanobubbles can reduce the hypoxic effect on the epithelial-to-mesenchymal transition (EMT) and prevent migration and invasion in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Methods
Using the sonic cavitation method, we have developed a method to generate bulk oxygen nanobubbles (ONBs) with dipalmitoyl phosphatidylcholine (DPPC) lipid and quantitate mean diameter and number density through nanoparticle tracking analysis and insight. We have treated A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cell lines with 1% oxygen and ONB. We have also checked its preventive role in the zebrafish tumor xenograft model. We have measured HIF-1a and EMT expression markers by immunoblot and qPCR analysis. Moreover, we have used the 4T1 BALB/c mice tumor xenograft model for further confirmation.
Results
ONB promotes HIF-1α hydroxylation and its proteasomal degradation in hypoxic cancer cells. ONBs treated A549 and MDA-MB-231 cancer cells and an adult zebrafish A549 tumor xenografts showed the downregulation of TGF-β and VEGFA expression at the transcriptional and translational levels, which also led to upregulation of epithelial genes like E-cadherin with down-regulation of mesenchymal genes like N cadherin, Vimentin, Fibronectin. ONB treatment significantly affects cancer cell migration. Also, liposomal ONB administrated 4T1 BALB/c breast tumor xenograft model showed similar results.
Conclusions
ONBs reduce HIF-1 mediated epithelial to mesenchymal transition (EMT) controlled by TGF-b and VEGFA and prevent cellular migration and invasion in solid tumors, particularly NSCLC and TNBC. In conclusion, targeted administration of ONB could be a better therapeutic approach to inhibit the hypoxic detrimental effect, which helps to increase the efficacy of anticancer treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Science and Technology (DST) Project, India (DSTSERB- ECR/2016/000288Department of Science and Technology (DST) Project, India (DSTSERB- DST (Department of Science and Technology) Project India, ECR/2016/000288.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2256P - The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study
Presenter: Yeonghak Bang
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2258P - Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Presenter: Lidwien Smabers
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08